Abion to Participate in Bio Europe Spring 2024 "Focusing on Global LO Discussions"

Abion announced on the 13th that it will participate in 'BIO-Europe Spring 2024,' held in Barcelona, Spain, from the 18th to the 20th (local time).

Bio Europe is the largest pharmaceutical and biotech conference in Europe, held twice a year in spring and autumn, attended by global pharmaceutical and biotech industry stakeholders. This year marks its 30th edition, showcasing the latest biotech research achievements and development technologies, and discussing research collaboration and investment attraction.

Abion will introduce its key pipelines, including ABN401, ABN501, and ABN202. The company plans to focus on licensing discussions through partnering with domestic and international companies.

ABN401 is a targeted therapy for non-small cell lung cancer with c-MET (hepatocyte growth factor receptor) mutations. Interim results from the global Phase 2 clinical trial showed an objective response rate (ORR) of approximately 53%. In the treatment-naive patient group, the response rate was 75%, and only 8% of patients experienced grade 3 or higher adverse reactions in terms of safety. These results are superior to those of competing drugs, Novartis's Tabrecta and Merck's Tepmetko.

ABN501 is a novel target pipeline targeting Claudin 3. Due to the difficulty in antibody discovery, ABN501 is the only pipeline targeting Claudin 3.

ABN202 is a next-generation anticancer platform being developed based on antibody-cytokine fusion protein (ACFP) platform technology. In April, Abion will present research abstracts on three related technologies at the American Association for Cancer Research (AACR).

An Abion representative stated, "Following Bio Europe, we will participate in global conferences such as AACR and the American Society of Clinical Oncology (ASCO), conducting various partnering activities to achieve meaningful outcomes."